The overall evidence for the procedure is “insufficient” at present, but good enough to allow coverage, the agency says.

Some believe that future studies are still needed to tease out whether there are high-risk subgroups who will benefit.

A true test of durability will take many more years, but if the valve holds up, it’s “potentially a game changer,” say ...

The most read stories this past month detailed the passing of Dimitrios Karmpaliotis and news on Evoque and COVID-19.

When encountering elderly ACS patients, clinical judgement is important given the risks of bleeding, says Arnold Seto.

Overall age-adjusted mortality rates have fallen, but the poorest parts of the world aren’t sharing in the benefits.

The results suggest minimal health status benefits once TR has dropped by three grades, but further research is needed.

The findings highlight the importance of having an EP versed in lead management on the heart valve team, one expert says.

Labels for the Pfizer and Moderna shots, which already caution about myocarditis and pericarditis, will more strongly stress ...

There have been three deaths and no serious injuries tied to a problem affecting detection of the pumps, according to Abiomed ...

Permanent pacemaker rates were nearly 18% at 30 days but came down as sites gained experience with the new device.

The study led to questions about whether patients would be best served by being treated at high-volume centers of excellence.